Artiva Biotherapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Artiva Biotherapeutics, Inc. (ARTV) reported Revenue from Contract with Customer, Excluding Assessed Tax of $32.92 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-03-24
- Artiva Biotherapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-12-31 was $1.78M.
- Artiva Biotherapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-09-30 was $26.66M.
- Artiva Biotherapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2023-06-30 was $3.50M.
- Artiva Biotherapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $32.92M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $28.44M derived: sum of 2 quarters · filed 2025-03-24 | $31.93M derived: sum of 3 quarters · filed 2025-03-24 | $32.92M 10-K · filed 2025-03-24 |
| 2023-09-30 | $26.66M 10-Q · filed 2024-11-12 | $30.15M derived: sum of 2 quarters · filed 2024-11-12 | $31.14M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $3.50M 10-Q · filed 2024-08-29 | $4.49M 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |